Epsilogen announces significant expansion of management team with three new senior hires
Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, announced three new senior hires in what is a significant expansion of their management team. Nick Robbins-Cherry joins as Chief Financial Officer, Andrew Calam as Vice President of Clinical Operations and Elizabeth Hardaker as Vice President of Biology.
Nick Robbins-Cherry, CFO, brings over 30 years of experience in fundraising, public markets and private equity, gained through financial and commercial roles in international pharmaceuticals and technology businesses. Most recently, Nick was CFO of Ixaka Ltd, a private cell and gene therapy company. Prior to this, Nick was CFO at Midatech Pharma PLC, a listed pharmaceutical business with operations in the UK and Spain. He successfully steered Midatech through its IPO on AIM, a dual listing on NASDAQ and subsequent fundraises. Nick is a Chartered Accountant and holds an MBA.
Andrew Calam, VP of Clinical Operations, has over 25 years of experience in the life sciences industry, holding both management and executive positions in the contract research organisation (CRO) and biotechnology sectors, leading and supporting pharmaceutical development. Andrew started his career within the bioanalytical space, before turning his focus to project management. He has a track record of leading multinational teams with responsibility for all aspects of clinical trial management from phase I to phase III trials. Prior to joining Epsilogen, Andrew worked as an Executive Director of Clinical Development at Syneos Health where he was responsible for the development, oversight, execution and management of several clinical programs for targeted cancer therapies.
Elizabeth Hardaker, VP of Biology, joins Epsilogen with over 15 years’ experience in the pharmaceutical industry. Most recently, Elizabeth was a Senior Director at AstraZeneca, leading a team supporting preclinical research in Oncology. Previously, Elizabeth worked at Evotec in the inflammation and immunology group, and Novartis in the respiratory group. Throughout her career Elizabeth has been the biology lead on a number of projects across the drug discovery process, ranging from target validation to clinical trials. Elizabeth has a PhD from the National Heart and Lung Institute, Imperial College and a Masters in Biochemistry from Bath University.
Tim Wilson, Chief Executive Officer of Epsilogen, commented:
“We are delighted to have Elizabeth, Andrew and Nick join our leadership team and we are pleased that we have been able to attract such high-calibre people to Epsilogen. They join the Company at an exciting stage of its development with lead asset MOv18 IgE having successfully completed a phase I clinical trial in ovarian cancer patients and progress being made within our IgE-based therapeutic platforms.”
ENDS
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defense against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity also seen. The company is also developing a proprietary IGEGTM antibody platform combining elements from both IgE and IgG antibodies into novel and proprietary antibody molecules with enhanced functionality.
Epsilogen began operations in 2017 as a spin out of King’s College London and has attracted investment funding from top tier investors including Epidarex Capital, Novartis Venture Fund, British Patient Capital, 3B Future Health Fund, ALSA Ventures and Schroders Capital. Find out more at epsilogen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005971/en/
Contact information
Communications advisor to Epsilogen Ltd:
Simon Conway / Rob Winder
FTI Consulting
epsilogen@fticonsulting.com
+44 (0)20 3727 1000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hanshow and Delfi Partner to Expand Digital Solutions in Europe15.9.2025 11:04:00 EEST | Press release
Hanshow, a global leader in Electronic Shelf Labels (ESLs) and digital retail solutions, and Delfi Technologies, a Danish retail technology pioneer with decades of expertise in ESL platforms, today announced a new partnership, marking the start of closer cooperation to expand ESL offerings for retailers across Europe and accelerate the next phase of in-store digital transformation. Through this partnership, Delfi Technologies’ Breece System platform will be strengthened with Hanshow’s world-class ESL portfolio, proven in thousands of deployments worldwide. This partnership combines Delfi’s experience with ESL deployments in Europe and Hanshow’s global innovation leadership. Together, Hanshow will bring more flexibility, more options, and more value to retailers, helping them accelerate their digital transformation with lower costs and greater impact. The partnership also reinforces both companies’ commitment to sustainability. By replacing paper-based processes with digital price manag
SES Partners with Cailabs to Test Next-Generation Laser Communication Technology15.9.2025 11:00:00 EEST | Press release
SES, a leading space solutions company, announced today it will test new optical ground stations built by France-based Cailabs to send data from space using laser beams instead of radio waves. By using optical communication, SES expects to be able to boost data transmission speeds, provide more secure links, and help alleviate congestion in increasingly crowded radio frequency bands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915922379/en/ SES Partners with Cailabs to Test Next-Generation Laser Communication Technology. Credit: Cailabs The partnership marks a major step forward for optical communications, which use light beams to transmit data at speeds of up to 10 gigabits per second—about 100 times faster than typical home internet. Unlike traditional radio signals, laser beams are nearly impossible to intercept or jam, making them ideal for secure government and business communications. The biggest challenge with o
Prometheus Slashes Cost of Carbon Capture by More Than 80%, Unlocking Affordable E-Fuels as a New Source of 24/7 Carbon Neutral Power15.9.2025 11:00:00 EEST | Press release
Prometheus Fuels (Prometheus), the company producing low-cost carbon neutral fuels from direct air capture and renewable electricity, today announced it has achieved the lowest-cost carbon capture in the world, reducing the cost of Direct Air Capture (DAC) by more than 80 percent compared to industry averages. At under $50 per ton, Prometheus’ DAC cost breakthrough unlocks carbon neutral fuels at fossil fuel prices, without relying on subsidies, biogenic carbon, or point-source emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915079297/en/ Prometheus builds a 200-ton-per-year Direct Air Capture system at its California HQ, adding capacity to its currently operating 16-TPY system, the world’s lowest-cost DAC technology at less than $50 per ton CO₂. The achievement is demonstrated in Prometheus’ new 200-ton-per-year DAC system, currently under construction and scheduled for completion this year. The system captures
LSEG Launches Digital Markets Infrastructure Platform for Private Funds, and Facilitates First Transaction15.9.2025 10:25:00 EEST | Press release
LSEG today announces that it has launched its Digital Markets Infrastructure (“DMI”) platform for private funds and facilitated its first transaction. DMI, which is powered by Microsoft Azure, will deliver blockchain-powered scale and efficiencies for the full asset lifecycle – from issuance, tokenisation and distribution to post trade asset settlement and servicing, across multiple asset classes. LSEG will ensure that this platform is interoperable with current market solutions in distributed ledger technology as well as traditional finance, fully utilising a range of the group's products and services, including Workspace. Developed in collaboration with Microsoft, DMI is aligned with LSEG’s goal of being the first global exchange group to support customers across the full funding continuum, alongside other group initiatives such as the Private Securities Market. Private funds is the first asset class to benefit from the DMI platform, with expansion to additional asset classes planned
Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 202515.9.2025 10:15:00 EEST | Press release
DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose biosensing technology for people with all types of diabetes at the upcoming 61st annual European Association for the Study of Diabetes (EASD) Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915690916/en/ Findings will demonstrate how CGM can reduce neonatal complications linked to gestational diabetes more effectively than fingersticks. “Each year, EASD provides a high-profile opportunity to highlight our latest product innovations and new clinical data that demonstrates how Dexcom glucose biosensing technology can empower people with all types of diabetes across the globe to take control of their health, while reinforcing Dexcom CGM as a cost-effective solution for diabetes management,” said Jake Leach, president and chief operating offic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom